Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 13/20 | 0.63 |
| ▸ | MEN1 | O00255 | 11/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.63 |
| ▸ | POLB | P06746 | 9/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.63 |
| ▸ | FLT3 | P36888 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 13/20 | 0.60 |
| ▸ | NPC1 | O15118 | 10/20 | 0.60 |
| ▸ | LMNA | P02545 | 9/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.60 |
| ▸ | HPGD | P15428 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | RECQL | P46063 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | PARP1 | P09874 | 1/20 | 0.57 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1080717 | 1.00 | SMN1; SMN2 (0.63) | SMN1; SMN2MEN1KMT2APOLBKDM4E | |
| SCHEMBL3163184 | 0.81 | SMN1; SMN2 (0.54) | SMN1; SMN2MEN1KMT2APOLBKDM4E | |
| SCHEMBL3163180 | 0.81 | SMN1; SMN2 (0.54) | SMN1; SMN2MEN1KMT2APOLBKDM4E | |
| SCHEMBL3923490 | 0.76 | FLT3 (1.00) | SMN1; SMN2MEN1KMT2APOLBKDM4E | |
| SCHEMBL3923491 | 0.76 | FLT3 (1.00) | SMN1; SMN2MEN1KMT2APOLBKDM4E | |
| SCHEMBL11924524 | 0.74 | TSHR (0.63) | SMN1; SMN2MEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL19889048 | 0.72 | TSHR (0.60) | SMN1; SMN2MEN1KMT2APOLBKDM4E | |
| SCHEMBL21959213 | 0.72 | SMN1; SMN2 (1.00) | SMN1; SMN2MEN1KMT2APOLBKDM4E | |
| SCHEMBL3109465 | 0.70 | NPC1 (0.77) | SMN1; SMN2MEN1KMT2APOLBKDM4E | |
| SCHEMBL11424329 | 0.69 | MAPT (0.74) | SMN1; SMN2MEN1KMT2APOLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120134963-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2012-05-31 | — | — | US | claimed |
| EP-2451795-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | Ottawa Hospital Research Institute (CA) | 2012-05-16 | — | — | EP | claimed |
| WO-2011003191-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2011-01-13 | — | — | WO | claimed |
| EP-2451795-B1 | COMPOSITIONS AND USES FOR ENHANCING VIRUS PRODUCTION | OTTAWA HOSPITAL RES INST (CA) | 2016-07-13 | — | — | EP | disclosed |
| US-9283254-B2 | Compositions and methods for enhancing virus efficacy | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2016-03-15 | — | — | US | disclosed |
| US-9283254-B2 | Compositions and methods for enhancing virus efficacy | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2016-03-15 | — | — | US | disclosed |
| US-20150202240-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2015-07-23 | — | — | US | disclosed |
| US-20150202240-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2015-07-23 | — | — | US | disclosed |
| US-20150202240-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2015-07-23 | — | — | US | disclosed |
| US-8940291-B2 | Compositions and methods for enhancing virus efficacy | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2015-01-27 | — | — | US | disclosed |
| US-8940291-B2 | Compositions and methods for enhancing virus efficacy | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2015-01-27 | — | — | US | disclosed |
| US-8940291-B2 | Compositions and methods for enhancing virus efficacy | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2015-01-27 | — | — | US | disclosed |
| US-20120134963-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2012-05-31 | — | — | US | disclosed |
| US-20120134963-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2012-05-31 | — | — | US | disclosed |
| US-20120134963-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2012-05-31 | — | — | US | disclosed |
| EP-2451795-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | Ottawa Hospital Research Institute (CA) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011003191-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134963-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | HAVCR2, MAVS, TSG101 | SMN1; SMN2 178/4885MEN1 2413/4885KMT2A 3799/4885 |
| US-20150202240-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VIRUS EFFICACY | HAVCR2, MAVS, TSG101 | SMN1; SMN2 178/4885MEN1 2413/4885KMT2A 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.